We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
97 hedge funds and large institutions have $47.9M invested in Galectin Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,421% more call options, than puts
Call options by funds: $6.14M | Put options by funds: $404K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
15% more funds holding
Funds holding: 84 → 97 (+13)
9% more capital invested
Capital invested by funds: $43.9M → $47.9M (+$3.96M)
1.84% more ownership
Funds ownership: 16.1% → 17.94% (+1.8%)
Holders
97
Holders Change
+13
Holders Change %
+15.48%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
28
Reduced
22
Closed
10
Calls
$6.14M
Puts
$404K
Net Calls
+$5.74M
Net Calls Change
+$5.18M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$1.5M |
| 2 |
Jane Street
New York
|
+$972K |
| 3 |
6CM
683 Capital Management
New York
|
+$856K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$749K |
| 5 |
Millennium Management
New York
|
+$659K |
